As population aging accelerates worldwide, aging-related diseases have become a major challenge in both life science and medicine. Aging is now widely recognized not as the failure of a single organ or pathway, but as a progressive, system-level process shaped by long-term interactions among genetic background, metabolic state, immune regulation, and environmental exposure. Over the past decade, extensive work has defined key molecular and cellular features of aging, including genomic instability, mitochondrial dysfunction, cellular senescence, immune dysregulation, and chronic inflammation. Together, these interconnected processes drive the gradual decline in tissue integrity and organ function with advancing age.
In a recent systematic review published online in Life Medicine, Prof. Feng Liu’s team from the Metabolic Syndrome Research Center at the Second Xiangya Hospital of Central South University proposes a new conceptual framework for aging. In the article entitled “Fat talks first: how adipose tissue sets the pace of aging? [1]”, the authors argue that adipose tissue may be among the earliest organs to exhibit detectable aging-related changes and may actively regulate the tempo of systemic aging.
Integrating evidence from single-cell transcriptomics, spatial omics, and functional studies, the review highlights that aging-associated alterations in adipose tissue[2], including progenitor cell dysfunction, immune imbalance, abnormal immunoglobulin accumulation, and amplification of senescence-associated secretory programs, can emerge as early as midlife. Importantly, these changes often precede dysfunction in many classical aging target organs.
The review highlights several directional changes that characterize adipose tissue aging: progressive loss of subcutaneous fat, ectopic expansion of visceral depots, adipocyte hypertrophy, increased fibrosis, and a pronounced decline in metabolic adaptability. These structural and metabolic alterations are accompanied by sustained immune imbalance, marked by reduced anti-inflammatory immune populations and accumulation of pro-inflammatory and senescent cells, ultimately establishing a state of chronic low-grade inflammation.
The authors emphasize that adipose tissue aging is not a passive bystander effect. Through adipokines, inflammatory mediators, extracellular vesicles, and metabolic stress signals, dysfunctional adipose tissue communicates extensively with the liver, skeletal muscle, cardiovascular system, and central nervous system. Once established, a self-reinforcing metabolic-immune imbalance within adipose tissue can propagate systemically, accelerating multi-organ functional decline.
The authors further discuss emerging biomarkers for assessing adipose tissue aging, including inflammatory cytokine profiles, immunoglobulin deposition, SASP-related signatures, and changes in adipokine secretion patterns[3]. Together, these markers suggest that adipose tissue aging exhibits definable and measurable biological features, supporting its potential use as an early window for aging assessment.
Overall, this review reframes adipose tissue as both an early responder and a signal amplifier in aging. By positioning adipose tissue at the center of aging chronology and regulation, the work provides a conceptual shift in how aging is viewed and suggests that targeting adipose tissue dysfunction may offer opportunities to move aging interventions to earlier, more effective stages, with the potential to extend healthspan.
DOI: 10.1093/lifemedi/lnaf028